すべての画像(2)
About This Item
実験式（ヒル表記法）:
Ru
CAS番号:
分子量:
101.07
MDL番号:
UNSPSCコード:
12141739
PubChem Substance ID:
NACRES:
NA.23
おすすめの製品
アッセイ
99.9%
形状
foil
メーカー／製品名
Goodfellow 853-285-23
抵抗性
7.1 μΩ-cm, 0°C
粒径
10 mm
bp
3900 °C (lit.)
mp
2310 °C (lit.)
密度
12.45 g/cm3 (lit.)
SMILES記法
[Ru]
InChI
1S/Ru
InChI Key
KJTLSVCANCCWHF-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
For updated SDS information please visit www.goodfellow.com.
法的情報
Goodfellow製品
保管分類コード
13 - Non Combustible Solids
WGK
nwg
引火点(°F)
Not applicable
引火点(℃)
Not applicable
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Kay Severin
Chimia, 66(6), 386-388 (2012-08-09)
Certain ruthenium complexes are potent catalysts for atom transfer radical addition (ATRA) and cyclization (ATRC) reactions, in particular if they are used in conjunction with reducing agents such as magnesium. This short overview summarizes recent developments in this area with
Elia Tfouni et al.
Nitric oxide : biology and chemistry, 26(1), 38-53 (2011-12-20)
Nitric oxide plays an important role in various biological processes, such as neurotransmission, blood pressure control, immunological responses, and antioxidant action. The control of its local concentration, which is crucial for obtaining the desired effect, can be achieved with exogenous
E Tfouni et al.
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Martin R Gill et al.
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）